Welcome!

News Feed Item

Collaboration Results, Litigation Update, Market Activity, Earnings Release, and Clinical Trial Results - Research Reports on Aetna, Allergan, Valeant, Perrigo and Baxter

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, September 1, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Aetna Inc. (NYSE: AET), Allergan Inc. (AGN: AGN), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Perrigo Company Public Limited Company (NYSE: PRGO) and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6107-100free.

--
Aetna Inc. Research Reports
On August 27, 2014, Aetna Inc. (Aetna) announced that its accountable care collaboration with Banner Health Network (BHN) has resulted in c.$5 million of shared savings on Aetna Whole Health fully-insured commercial membership in 2013 and also witnessed a 5% decline in average medical cost on the members. According to the Company, the collaboration also resulted in improved cancer screening rates, blood sugar management in diabetic members and reduced avoidable hospital admissions. Chuck Lehn, BHN's CEO said, "Aetna and BHN have a collaborative relationship that is to the benefit of our members and employers. These results are rewarding because they validate our model- it is possible to deliver quality care at more affordable prices." The full research reports on Aetna are available to download free of charge at:

http://www.analystsreview.com/Sep-01-2014/AET/report.pdf

--
Allergan Inc. Research Reports
On August 26, 2014, Allergan Inc. (Allergan) announced that it has requested the United States District Court for the Central District of California to set an expedited schedule for discovery and a motion for a preliminary injunction against Valeant Pharmaceuticals (Valeant), Pershing Square Capital Management, L.P. (Pershing Square), and its principal, William A. Ackman for violating federal securities laws. The Company also announced a Special Meeting of Stockholders to be held on December 18, 2014 in which shareholders of record at the close of business on October 27, 2014 will be entitled to vote. According to the Company, in its preliminary injunction movement, it will seek an order barring Valeant, Pershing Square, Mr. Ackman, and individuals affiliated with them from exercising any rights or benefits associated with Allergan shares that might have been acquired illegitimately and would prevent Valeant, Pershing Square, and Mr. Ackman from voting their shares in any special meeting. The full research reports on Allergan are available to download free of charge at:

http://www.analystsreview.com/Sep-01-2014/AGN/report.pdf

--
Valeant Pharmaceuticals International, Inc. Research Reports
On August 27, 2014, Valeant Pharmaceuticals International, Inc.'s (Valeant) stock declined 0.33% to end the trading session at $116.71. During the day, the stock opened at $118.25 and fluctuated within the range of $115.60 and $118.39, with a total of 1.35 million shares changing hands. Valeant's stock underperformed Dow Jones Industrial Average index which ended the session 0.09% higher. The full research reports on Valeant are available to download free of charge at:

http://www.analystsreview.com/Sep-01-2014/VRX/report.pdf

--
Perrigo Company Public Limited Company Research Reports
On August 14, 2014, Perrigo Company Public Limited Company (Perrigo) reported its Q4 FY 2014 and FY 2014 financial results (period ended June 28, 2014). The net sales for the quarter came in at $1.1 billion, up 18.3% YoY, mainly due to the new product sales of $65 million, $112 million attributable to the acquisition of Elan Corporation plc, and product acquisitions from Fera Pharmaceuticals, LLC and Aspen Global Inc. Net sales for FY 2014 came in at $4.1 billion, up 14.7% YoY, primarily led by $290 million in sales attributable to the Elan, Rosemont Pharmaceuticals, Ltd., Sergeant's Pet Care Products, Inc., Fera, Velcera Inc. and Aspen acquisitions and new product sales of $231 million. The net income for FY 2014 declined 53.5% YoY to $205.3 million, while net income for Q4 FY 2014 came in at $131.7 million, up 11.1% YoY. The Company expects diluted EPS for FY 2015 to range from $4.05 to $4.35 and net income to range from $546.1 million to $586.6 million. The full research reports on Perrigo are available to download free of charge at:

http://www.analystsreview.com/Sep-01-2014/PRGO/report.pdf

--
Baxter International Inc. Research Reports
On August 21, 2014, Baxter International Inc. (Baxter) announced encouraging results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)]. Top-line results from the study demonstrated that BAX 855 achieved its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. According to the Company, patients in a twice-weekly prophylaxis arm experienced a 95% reduction in median annualized bleed rates versus those in the on-demand arm. Baxter added that it anticipates submitting a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before 2014 year-end and will present additional data in the coming months. The full research reports on Baxter are available to download free of charge at:

http://www.analystsreview.com/Sep-01-2014/BAX/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


AnalystsReview.com

SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Avere Systems, a leading provider of enterprise storage for the hybrid cloud, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Avere delivers a more modern architectural approach to storage that doesn't require the overprovisioning of storage capacity to achieve performance, overspending on expensive storage media for inactive data or the overbui...
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...
Though cloud is the future of enterprise computing, a smooth transition of legacy applications and systems is critical for seamless business operations. IT professionals are eager to start leveraging the cost, scale and other benefits of cloud, but with massive investments already in place in existing infrastructure and a number of compliance and resource hurdles, it can be challenging to move to a cloud-based infrastructure.
Containers are rapidly finding their way into enterprise data centers, but change is difficult. How do enterprises transform their architecture with technologies like containers without losing the reliable components of their current solutions? In his session at @DevOpsSummit at 21st Cloud Expo, Tony Campbell, Director, Educational Services at CoreOS, will explore the challenges organizations are facing today as they move to containers and go over how Kubernetes applications can deploy with lega...
SYS-CON Events announced today that Avere Systems, a leading provider of hybrid cloud enablement solutions, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Avere Systems was created by file systems experts determined to reinvent storage by changing the way enterprises thought about and bought storage resources. With decades of experience behind the company’s founders, Avere got its ...
Amazon is pursuing new markets and disrupting industries at an incredible pace. Almost every industry seems to be in its crosshairs. Companies and industries that once thought they were safe are now worried about being “Amazoned.”. The new watch word should be “Be afraid. Be very afraid.” In his session 21st Cloud Expo, Chris Kocher, a co-founder of Grey Heron, will address questions such as: What new areas is Amazon disrupting? How are they doing this? Where are they likely to go? What are th...
Today most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes significant work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reducti...
As hybrid cloud becomes the de-facto standard mode of operation for most enterprises, new challenges arise on how to efficiently and economically share data across environments. In his session at 21st Cloud Expo, Dr. Allon Cohen, VP of Product at Elastifile, will explore new techniques and best practices that help enterprise IT benefit from the advantages of hybrid cloud environments by enabling data availability for both legacy enterprise and cloud-native mission critical applications. By rev...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous ar...
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, will discuss how they b...
SYS-CON Events announced today that SkyScale will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. SkyScale is a world-class provider of cloud-based, ultra-fast multi-GPU hardware platforms for lease to customers desiring the fastest performance available as a service anywhere in the world. SkyScale builds, configures, and manages dedicated systems strategically located in maximum-security...
As you move to the cloud, your network should be efficient, secure, and easy to manage. An enterprise adopting a hybrid or public cloud needs systems and tools that provide: Agility: ability to deliver applications and services faster, even in complex hybrid environments Easier manageability: enable reliable connectivity with complete oversight as the data center network evolves Greater efficiency: eliminate wasted effort while reducing errors and optimize asset utilization Security: imple...
High-velocity engineering teams are applying not only continuous delivery processes, but also lessons in experimentation from established leaders like Amazon, Netflix, and Facebook. These companies have made experimentation a foundation for their release processes, allowing them to try out major feature releases and redesigns within smaller groups before making them broadly available. In his session at 21st Cloud Expo, Brian Lucas, Senior Staff Engineer at Optimizely, will discuss how by using...
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lead...
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...